Evaluating the treatment of metastatic colorectal cancer with monoclonal antibodies.

J Med Life · 2012 · PMC3391878 · PMID 22802884

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, in the K-RAS mutant group, RR showed a trend toward a worse rate in the cetuximab plus FOLFOX4 arm (33%) vs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.